StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note issued to investors on Saturday morning. The firm issued a sell rating on the stock.
OncoCyte Trading Down 0.7 %
NASDAQ OCX opened at $2.88 on Friday. OncoCyte has a 1 year low of $2.08 and a 1 year high of $7.20. The company’s 50 day simple moving average is $2.98 and its two-hundred day simple moving average is $3.08.
Hedge Funds Weigh In On OncoCyte
Several institutional investors and hedge funds have recently made changes to their positions in OCX. Millennium Management LLC bought a new position in shares of OncoCyte during the 2nd quarter valued at $896,000. Geode Capital Management LLC grew its holdings in shares of OncoCyte by 23.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,228,553 shares of the company’s stock valued at $283,000 after purchasing an additional 236,099 shares during the last quarter. Vanguard Group Inc. grew its holdings in OncoCyte by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 3,986,270 shares of the company’s stock worth $5,940,000 after acquiring an additional 90,534 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in OncoCyte by 17.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 541,983 shares of the company’s stock worth $487,000 after acquiring an additional 81,979 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in OncoCyte by 131.7% in the 2nd quarter. Renaissance Technologies LLC now owns 138,100 shares of the company’s stock worth $32,000 after acquiring an additional 78,500 shares during the last quarter. Institutional investors own 55.35% of the company’s stock.
About OncoCyte
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
Read More
- Five stocks we like better than OncoCyte
- Why Are Stock Sectors Important to Successful Investing?
- 4 Golden Crosses With Double-Digit Upside Ahead
- What Are Dividends? Buy the Best Dividend Stocks
- All-Aboard! Greenbrier Companies Breaks Out, New Highs Ahead
- What is Short Interest? How to Use It
- 3 High Dividend Socks to Replace Lower Savings Yields Ahead
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.
